Literature DB >> 3021932

Computerized tomography in the prognosis of malignant cerebral gliomas.

J Murovic, K Turowski, C B Wilson, T Hoshino, V Levin.   

Abstract

Ninety-seven patients with supratentorial malignant gliomas who received postoperative radiation therapy and chemotherapy at the University of California, San Francisco, from 1977 through 1984 showed improvement in their follow-up computerized tomography (CT) scans. Twenty-one of these 97 "CT responders" were designated "complete responders" because on serial CT scans they had complete disappearance of the tumor mass and contrast enhancement, which had been present postoperatively. In the remaining 76 patients, CT scans showed reduction in the size, but not disappearance, of the lesions, and these were designated "partial responders." Fifty-eight partial responders had glioblastoma multiforme (GM); their median survival time was 72 weeks. The median survival time for the 11 complete responders with GM has not yet been achieved, but survival at the 53rd percentile is 172 weeks. Among patients with highly anaplastic astrocytoma, the median survival time was 211 weeks for the 10 complete responders and 125 weeks for the 18 partial responders. Eleven of the 21 complete responders are alive at a median postoperative follow-up time of 163 weeks (range 114 to 470 weeks). Eighteen of these patients had subtotal resection of tumor; three patients had gross total tumor resections, but postoperative CT scans showed evidence of residual or possibly recurrent tumor within 1.5 to 4.5 months. Resolution of the tumor mass and contrast enhancement took 9 to 151 weeks; the time to resolution did not depend upon the configuration of the remaining tumor mass and contrast enhancement after surgery. In this study, patients with malignant gliomas whose CT scans eventually showed sustained complete disappearance of the tumor mass and contrast enhancement had a more favorable prognosis than did patients whose CT scans showed improvement, but not complete disappearance, of the tumor. These CT findings may prove useful in determining the prognosis of patients with malignant gliomas.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3021932     DOI: 10.3171/jns.1986.65.6.0799

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  8 in total

1.  Changes in glucose uptake by malignant gliomas: preliminary study of prognostic significance.

Authors:  J M Rozental; R L Levine; R J Nickles
Journal:  J Neurooncol       Date:  1991-02       Impact factor: 4.130

2.  Brain Tumor Working Group Report on the 9th International Conference on Brain Tumor Research and Therapy. Organ System Program, National Cancer Institute.

Authors:  D F Deen; A Chiarodo; E A Grimm; J R Fike; M A Israel; L E Kun; V A Levin; L J Marton; R J Packer; A E Pegg
Journal:  J Neurooncol       Date:  1993-06       Impact factor: 4.130

3.  Radiation therapy combined with radiosensitizing agents for cerebral glioblastoma in adults.

Authors:  M Matsutani; O Nakamura; M Nakamura; T Nagashima; A Asai; T Fujimaki; H Tanaka; K Ueki; Y Tanaka
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

4.  Intra-operative radiation therapy for malignant brain tumors: rationale, method, and treatment results of cerebral glioblastomas.

Authors:  M Matsutani; O Nakamura; T Nagashima; A Asai; T Fujimaki; H Tanaka; M Nakamura; K Ueki; Y Tanaka; T Matsuda
Journal:  Acta Neurochir (Wien)       Date:  1994       Impact factor: 2.216

5.  Development of supratentorial astrocytomas.

Authors:  A Huber; J Simbrunner; A Witzmann; J Fischer
Journal:  Neurosurg Rev       Date:  1993       Impact factor: 3.042

6.  Influence of extent of surgery and tumor location on treatment outcome of patients with glioblastoma multiforme treated with combined modality approach.

Authors:  B Jeremic; D Grujicic; V Antunovic; L Djuric; M Stojanovic; Y Shibamoto
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

7.  Effects of radiotherapy after hyperbaric oxygenation on malignant gliomas.

Authors:  K Kohshi; Y Kinoshita; H Imada; N Kunugita; H Abe; H Terashima; N Tokui; S Uemura
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

8.  Impact of phase II trials with progression-free survival as end-points on survival-based phase III studies in patients with anaplastic gliomas.

Authors:  Victor A Levin; Sandra Ictech; Kenneth R Hess
Journal:  BMC Cancer       Date:  2007-06-22       Impact factor: 4.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.